Biogen Idec Spokesperson Refutes Claims of Biopharm Insight Article

Biogen

spokesperson says there has been no increase in malignancies in BG-12 clinical trial. No data has been released. Spokesperson says Biopharm Insight had said previously that Biogen's filings would be delayed and they were not.